Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer

There is still a big gap from the basic research (bench) to the clinical use (bed) in precise and personal therapy for patients with epithelial ovarian cancer (EOC) [1]. Because of slow progress in improving the outcome of EOC with chemotherapy over the past three decades, enthusiasm swelled for one of the targeted therapy, such as poly(ADP-ribose) polymerase (PARP) inhibitors which might be a part of the current treatment strategy when the positive results from the randomized, placebo-controlled, phase 3 trial (ENGOT-OV16/NOVA) conducted by the European Network for Gynecological Oncological Trial groups was obtained and published in The New England Journal of Medicine [2].
Source: Taiwanese Journal of Obstetrics and Gynecology - Category: OBGYN Authors: Tags: Correspondence Source Type: research